Dipyridamole
- Generic Name
- Dipyridamole
- Brand Names
- Aggrenox, Persantine
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40N8O4
- CAS Number
- 58-32-2
- Unique Ingredient Identifier
- 64ALC7F90C
- Background
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
- Indication
For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
- Associated Conditions
- Coronary Artery Disease (CAD), Postoperative Thromboembolism, Stroke, Thrombosis, Transient Ischemic Attack
- Associated Therapies
- Anti-platelet Therapy
Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)?
- Conditions
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 95
- Registration Number
- NCT01295567
- Locations
- 🇳🇱
RUNMC, Nijmegen, Netherlands
The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2010-11-05
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01091571
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
"Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2009-08-18
- Lead Sponsor
- Hillel Yaffe Medical Center
- Registration Number
- NCT00960817
- Locations
- 🇮🇱
Hillel Yaffe Medical Center, Hadera, Israel
Persantin Preceding Elective PCI
- Conditions
- Interventions
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00767663
- Locations
- 🇳🇱
RUNMC, Nijmegen, Netherlands
🇳🇱Canisius Wilhelmina Hospital, Nijmegen, Netherlands
Persantine: Variation in Response Trial
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 8
- Registration Number
- NCT00763009
- Locations
- 🇺🇸
UCONN Health Center, Farmington, Connecticut, United States
Efficacy of Allopurinol and Dypiridamole in Acute Mania
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Hospital Espirita de Porto Alegre
- Target Recruit Count
- 180
- Registration Number
- NCT00560079
- Locations
- 🇧🇷
Hospital Espirita de Porto Alegre, Porto Alegre, RS, Brazil
Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Zalicus
- Target Recruit Count
- 51
- Registration Number
- NCT00551707
Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00457405
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?
- Conditions
- Interventions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2008-07-29
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00430170
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Clinical Trial of Dipyridamole in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 29
- Registration Number
- NCT00349973
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.